0001209191-19-053335.txt : 20191016 0001209191-19-053335.hdr.sgml : 20191016 20191016201916 ACCESSION NUMBER: 0001209191-19-053335 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191014 FILED AS OF DATE: 20191016 DATE AS OF CHANGE: 20191016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aurentz Vincent CENTRAL INDEX KEY: 0001657494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 191153717 BUSINESS ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 453-7200 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Vincent Aurentz DATE OF NAME CHANGE: 20151103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-14 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001657494 Aurentz Vincent C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 Executive VP and CBO Common Stock 2019-10-14 4 M 0 9000 0.00 A 9000 D Performance Restricted Stock Unit 2019-10-14 4 M 0 9000 0.00 D 2022-01-03 Common Stock 9000 27000 D On January 4, 2019, the Reporting Person was granted 18,000 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 9,000 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 27,000 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 27,000 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2019-10-16